Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.53 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | ARG1 | P05089 | 1/20 | 0.48 |
| ▸ | ARG2 | P78540 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264740 | 0.81 | ARG1 (0.53) | FDPSALDH1A1CYP3A4GABRA1TSHR | |
| SCHEMBL2264734 | 0.81 | ARG1 (0.53) | FDPSALDH1A1CYP3A4GABRA1TSHR | |
| SCHEMBL502104 | 0.75 | PKM (0.52) | FDPSALDH1A1TSHRNFKB1KDM4E | |
| SCHEMBL20644246 | 0.75 | HRH4 (0.57) | FDPSALDH1A1CYP3A4GABRA1TSHR | |
| SCHEMBL3510790 | 0.73 | ALDH1A1 (0.59) | FDPSALDH1A1CYP3A4GABRA1TSHR | |
| SCHEMBL30165180 | 0.73 | LNPEP (0.52) | ALDH1A1CYP3A4NFKB1HRH3HRH4 | |
| SCHEMBL11611208 | 0.72 | ARG1 (0.51) | FDPSALDH1A1CYP3A4GABRA1TSHR | |
| SCHEMBL11159616 | 0.72 | ARG1 (0.61) | FDPSALDH1A1CYP3A4GABRA1TSHR | |
| SCHEMBL11154182 | 0.72 | ARG1 (0.61) | FDPSALDH1A1CYP3A4GABRA1TSHR | |
| SCHEMBL14198967 | 0.72 | QPCT (0.49) | FDPSALDH1A1CYP3A4GABRA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0904275-B1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | UNIV MCGILL (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-6861518-B2 | Hybrid oligonucleotide | MCGILL UNIVERSITY (CA) | 2005-03-01 | — | — | US | disclosed |
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY | 2004-05-20 | — | — | US | disclosed |
| US-20030229219-A1 | Preparation of phosphorothioate oligomers | ISIS PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-6596857-B1 | Oligomer for use as tool in human diagnostics and therapeutics | MCGILL UNIVERSITY (CA) | 2003-07-22 | — | — | US | disclosed |
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | JUST GEORGE (CA) | 2003-06-19 | — | — | US | disclosed |
| US-6476216-B1 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 2002-11-05 | — | — | US | disclosed |
| US-6160109-A | Preparation of phosphorothioate and boranophosphate oligomers | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6031092-A | Preparation of phosphorothioate oligomers | MC GILL UNIVERSITY (CA) | 2000-02-29 | — | — | US | disclosed |
| US-5945521-A | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 1999-08-31 | — | — | US | disclosed |
| EP-0904275-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | McGILL UNIVERSITY (CA) | 1999-03-31 | — | — | EP | disclosed |
| US-5734041-A | Preparation of chiral phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 1998-03-31 | — | — | US | disclosed |
| WO-1997014710-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | MCGILL UNIVERSITY (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | FDPS 894/4885ALDH1A1 3421/4885CYP3A4 4574/4885 |
| US-20030229219-A1 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | FDPS 894/4885ALDH1A1 3421/4885CYP3A4 4574/4885 |
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | FDPS 894/4885ALDH1A1 3421/4885CYP3A4 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.